Share ownership Pharmaron Beijing Co., Ltd.

300759

CNE100003JW4

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2026-01-16			5-day change	1st Jan Change
31.94 ^CNY	-2.56%		+1.11%	+12.35%

Jan. 14	Pharmaron Beijing to place 58.4 million new H shares at RMB1.00 per share	RE
Jan. 14	Pharmaron Beijing Seeking HK$1.33 Billion via Stock Offering	MT

Share class: Pharmaron Beijing Co., Ltd.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	294,273,825	0	0	48.56 %
Stock B	1	1,476,658,400	859,998,575 ( 58.24 %)	0

Major shareholders: Pharmaron Beijing Co., Ltd.

Name	Equities	%	Valuation
CITIC M&A Fund Management Co. Ltd. 18.62 %	264,598,500	18.62 %	1 076 M ¥
Bo Liang Lou 12.7 %	180,496,500	12.7 %	734 M ¥
Xiao Qiang Lou 7.085 %	100,675,076	7.085 %	410 M ¥
Zhong Ou Asset Management Co., Ltd 4.533 %	64,410,398	4.533 %	262 M ¥
Bei Zheng 2.959 %	42,040,974	2.959 %	171 M ¥
Hwabao WP Fund Management Co., Ltd. 2.108 %	29,946,981	2.108 %	122 M ¥
Beihai Duotai Venture Capital Co., Ltd. 1.545 %	21,956,986	1.545 %	89 M ¥
China Merchants Fund Management Co., Ltd. 1.231 %	17,489,715	1.231 %	71 M ¥
Tian Hong Asset Management Co., Ltd. 1.224 %	17,392,967	1.224 %	71 M ¥
Huatai-PineBridge Fund Management Co., Ltd. 1.223 %	17,373,767	1.223 %	71 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Norges Bank Investment Management 4.824 %	14,545,724	4.824 %	37 M ¥
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 0.905 %	2,728,800	0.905 %	7 M ¥
ICBC UBS Asset Management Co. Ltd. 0.8464 %	2,552,285	0.8464 %	6 M ¥
Yinhua Fund Management Co., Ltd. 0.3947 %	1,190,300	0.3947 %	3 M ¥
JPMorgan Asset Management (Asia Pacific) Ltd. 0.3273 %	986,800	0.3273 %	2 M ¥
Fullgoal Fund Management Co., Ltd. 0.208 %	627,215	0.208 %	2 M ¥
Value Partners Hong Kong Ltd. 0.165 %	497,650	0.165 %	1 M ¥
Invesco Great Wall Fund Management Co. Ltd. 0.1376 %	414,800	0.1376 %	1 M ¥
State Street Global Advisors Ltd. 0.0714 %	215,438	0.0714 %	542 227 ¥
Wanjia Asset Management Co., Ltd. 0.0615 %	185,400	0.0615 %	466 626 ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Xiao Qiang Lou 70.66 %	45,405,037	70.66 %	185 M ¥

Breakdown by shareholder type

Institutional	168.95%
Individuals	122.25%
Other	15.7%

Based on 1000 largest holdings

Geographical origin of shareholders

China	178.74%
Individuals	122.25%
Norway	4.83%
Hong Kong	0.77%
United Kingdom	0.12%
Taiwan	0.1%
United States	0.03%
Ireland	0.03%
Germany	0.02%
Malaysia	0.01%

Based on 1000 largest holdings

Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

Employees

21,370

Sector

Biotechnology & Medical Research

Calendar

Mar. 29 - Q4 2025 Earnings Release (Projected)

More about the company